GuruFocus.com13d agobearish
Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent CliffMorgan Stanley Cuts Novo Nordisk to Underweight as Semaglutide Risks Cloud Outlook
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
144last 24h
877last 7d
147● bullish (7d)
98● bearish (7d)
214publishers
The Wall Street Journal28d agobearish
Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth ConcernsThe stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.
Investing.com50d agobearish
Novo Nordisk tumbles as Wegovy sales miss, trial setback overshadow raised outlookInvesting.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) hiked its full-year guidance, saying annual sales and operating profit should decline less than previously expected as demand for its weight-loss drugs continues unabated.